All News

EULAR flags

Understanding Comorbidities in RMD

2026 EULAR Press Release

People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.

Read Article
safety data

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal

Mrinalini Dey, MD

Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.

Read Article
RheumNow Podcast square

Count Your Telangiectasias (5.29.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and missed quiz questions.

Read Article

Catching up with the “Optimising care in SpA” at #EULAR2026 #OP0234 Phase 3 OLINGUITO trial showed filgotinib significantly improved ASAS40 responses vs PBO in both radiographic and non-radiographic axSpA by Week 16, with responses maintained through Week 52. @RheumNow #EULARBest https://t.co/axn6Zv52RA

Links:

Mrinalini Dey DrMiniDey ( View Tweet)

FASTLANE study Ph4 RCT on TOFA+NPX vs. PBO+NPX for early active axSpA TOFA arm significantly achieved inactive dse vs. PBO (p=0.006) at wk 16. Similar results seen in secondary efficacy endpts. Interesting results supporting TOFA use AbsOP0241 @RheumNow #EULAR2026 #EULARBest https://t.co/PQYzE1zm0h

Links:

sheila RHEUMarampa ( View Tweet)
TCZ vs ABA head-to-head in #RA after 1-2 prior b/tsDMARDs: SUNSTAR RCT (n=224) didn't hit its primary endpoint (CDAI change at wk 26, p=0.11). But composite response (treatment persistence + LDA + steroid-sparing) favored TCZ: 50.5% vs 35% (p=0.034). @RheumNow #EULAR2026 OP0205

Jiha Lee JihaRheum ( View Tweet)

RENOIR Ph2b pathogenic T-cell depletion rosnilimab RA -Primary endpoint DAS28-CRP change wk12 -2.06 to -2.12 (all doses) vs -1.69 PBO p<0.01 -ACR20/50/70 + CDAI LDA all improved vs PBO -hsCRP reduction across all dose arms -69% CDAI LDA by wk14 -wk 28 extension shows https://t.co/AMfmSded0D

Links:

Aurelie Najm AurelieRheumo ( View Tweet)

#EULAR2026 OP0166 In a phase III RCT in dermatomyositis, brepocitinib, first in class selective SyK-i and JAK1-i showed rapid meaningful improvement in cutaneous DM as early as Week 4 vs PBO. Exciting option and is under FDA Priority Review for approval @RheumNow #EULARBest https://t.co/9b0WurgBkN

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Mean disease duration in the tofacitinib arm was just 0.57 years since diagnosis. This is genuinely early #axSpA and JAK1 inhibition achieves near-remission rates above placebo. An oral option for early axSpA Abstr#0241 @RheumNow #EUlAR2026

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Tofacitinib achieved ASDAS inactive disease in 26.4% of patients with early #axSpA (back pain ≤2 years) vs 7.4% placebo at 16 weeks (p=0.006). First RCT of advanced therapy in very early axSpA Abstr#0241 @RheumNow #EULAR2026

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

What if we let RA patients choose ttmt? BACH RCT choice between Filgo / scTNFi vs. standard randomisation 55% JAKi vs 45% TNFi Higher ttmt satisfaction 46 vs 33 p=0.012 Less ttmt switches 6 vs 15 p=0.026 Less AE reported Better drug survival Shared decision making is key! https://t.co/1YS0y6YUEH

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Does ASA protect against JAKi-associated VTE in #RA? Swedish data (n=26,116): No. JAKi VTE risk remained elevated vs TNFi regardless of concomitant ASA or DOAC use. NSAIDs showed a non-significant trend toward protection. @RheumNow #EULAR2026 POS0068

Jiha Lee JihaRheum ( View Tweet)

📈 Do SIJ lesions progress in #axSpA? DESIR cohort (n=649, 10yrs): Yes, slowly, but bDMARDs reduce erosion progression #OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
Cancer risk with JAK inhibitors remains a major focus at #EULAR2026. In #OP086, analysis from 14 international RA registries and >60000 treatment courses found no statistically significant increase in overall or subtype-specific malignancy risk with JAKi versus TNFi. @RheumNow https://t.co/JeOmTufYwo

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
#OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
🎯 Does Tofacitinib work in axial #PsA? #POS0049: 1st RCT (PASTOR, n=26): improved MRI & clinical outcomes vs placebo @ wk12 #EULAR2026 @rheumnow

Nelly ZIADE 🍀 Nellziade ( View Tweet)

What’s in the pipeline for #psoriatic_arthritis treatment? A special focus on Tyk2 inhibitors WIN session at #EULAR2026 @RheumNow https://t.co/dDJtmdx9xU

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
What is new in PsA? Dennis McGonagle's take at #EULAR2026 -a strong year for discovery in mechanisms of transition from PSO to PsA -publication of the first single cell atlas Enthesis -Better understanding of VTE mechanisms in JAKi in PsA -clinical aspects of Axial involvement https://t.co/v9cfn1y4fH

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
DERM on RheumNow PODCAST (May 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, and other CTD skin disorders. Dermatology drugs, biologics, JAKs - their use, efficacy, and https://t.co/0AEAxadBFT
Dr. John Cush RheumNow ( View Tweet)
Review of Ruxolitinib in 7 pts w/ refractory systemic JIA complicated by macrophage activation (MAS) (ages 1.6-11 yrs; 3M: 4F). 5 achieved complete remission; 2 partial remission. 2 relapsed w/ GC tapering (remission after adding canakinumab). No deaths https://t.co/j4Cm3UYB9c https://t.co/pKoDwpSKII

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×